CSL agrees $355M upfront deal to co-develop Alentis anti-fibrosis drug for kidney and liver

CSL, an Australian drugmaker, announced a partnership with Alentis Therapeutics that includes a $355 million upfront payment.

Under the agreement, CSL will co-develop Alentis's anti-fibrosis candidate aimed at treating kidney and liver diseases, with the potential for up to $1.2 billion in additional milestone payments.

The collaboration expands CSL's pipeline in fibrosis therapeutics and provides Alentis with significant funding to advance the drug's development.